|1.||Formelli, Franca: 21 articles (12/2013 - 07/2002)|
|2.||Lovat, Penny E: 18 articles (01/2012 - 09/2002)|
|3.||Cavadini, Elena: 16 articles (02/2012 - 01/2003)|
|4.||Redfern, Christopher P F: 16 articles (04/2011 - 09/2002)|
|5.||Reynolds, C Patrick: 15 articles (01/2014 - 07/2003)|
|6.||Piacentini, Mauro: 14 articles (04/2011 - 09/2002)|
|7.||Decensi, Andrea: 13 articles (12/2013 - 07/2002)|
|8.||Maurer, Barry J: 12 articles (01/2014 - 07/2003)|
|9.||Decensi, A: 11 articles (10/2012 - 01/2000)|
|10.||Appierto, Valentina: 11 articles (01/2012 - 01/2003)|
02/01/2014 - "In addition, treatment with 4-HPR results in upregulation of MKK4 and MEKK1, and phosphorylation of MKK3/6. Efforts to enhance the efficacy of 4-HPR and to identify those tumors most likely to respond to it might exploit these effectors of 4-HPR-induced apoptosis. "
02/01/2004 - "In the older rats, lower doses of 9-cis-RA or 4-HPR alone were highly effective; with 61% and 46% reductions in the number of mammary cancers, respectively. "
11/01/1997 - "Both 9-cis-RA (0.1 and 0.2 mmol/kg diet) and 4-HPR (1 and 2 mmol/kg diet) were highly effective in decreasing the yield of AOM-induced colon tumors. "
01/01/2010 - "The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR) very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act synergistically in combination with the parent drug. "
12/01/2009 - "The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines. "
|2.||Breast Neoplasms (Breast Cancer)
04/01/2013 - "Promising results have been observed in the breast cancer prevention setting, where fenretinide prevention trials have provided a strong rationale for further investigation in young women at high risk for breast cancer. "
07/01/2010 - "Clinical trials have shown that fenretinide induces a significant reduction of second breast cancer in premenopausal women. "
04/01/2007 - "This warrants further research on the mechanisms of action and potential efficacy of fenretinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. "
01/01/1994 - "A phase III trial evaluating the efficacy of fenretinide for breast cancer prevention in high-risk women has been completed. "
11/03/1999 - "We determined the efficacy of fenretinide in preventing a second breast malignancy in women with breast cancer. "
09/29/2009 - "Results demonstrated that combination of 4-HPR and GST induced multiple molecular mechanisms for apoptosis and thus could be highly effective for inhibiting growth of malignant neuroblastoma in preclinical animal models."
02/01/2014 - "Pharmacological agents that enhance MKK4 or MEKK1 expression or JNK expression or phosphorylation may enhance efficacy of 4-HPR in neuroblastomas that do not express high levels of p75NTR."
11/01/2009 - "These results suggested that combination of 4-HPR and GST could be effective for controlling the growth of heterogeneous human neuroblastoma cell populations."
11/01/2004 - "Fenretinide, which mediates apoptosis in neuroblastoma cells, is being considered as a novel therapeutic for neuroblastoma. "
09/01/2003 - "However, because of the promising results of fenretinide on neuroblastoma growth in vitro, further in vivo studies are warranted using other modalities of drug administration."
02/08/1996 - "We previously reported that fenretinide (4HPR) is effective against a human ovarian carcinoma xenografted in nude mice. "
03/01/2005 - "Phase II trial of fenretinide in advanced renal carcinoma."
01/01/2010 - "Finally, our results demonstrated that fenretinide-induced expression of SPARC contributes significantly to a decreased invasion of mammary carcinoma cells. "
12/01/2008 - "At week 12, 16 carcinomas were detected in group 3 animals, but group 4 developed more carcinomas per animal than group 3. Using these experimental concentrations, 4-HPR cannot express its best chemopreventive effect."
09/15/2004 - "An unidentified polar metabolite was previously found in 4-HPR-treated subjects and in A2780 human ovarian carcinoma cells continuously treated with 4-HPR (A2780/HPR). "
|5.||Prostatic Neoplasms (Prostate Cancer)
01/01/2009 - "We conducted a phase II trial of oral fenretinide in patients with biochemically recurrent prostate cancer. "
02/01/2008 - "In our study, we investigate whether p-DDAP shows anticancer activity against human prostate cancer cell line PC-3 when compared with 4-HPR. "
03/01/1999 - "Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis."
10/01/2010 - "Fenretinide is a synthetic retinoid with activity in prostate cancer and other cell lines. "
01/01/2009 - "Although well-tolerated, oral fenretinide did not meet prespecified PSA criteria for response in biochemically recurrent prostate cancer; however, 30% of patients had SD, which suggests modest single-agent clinical activity. "
|2.||Tretinoin (Retinoic Acid)
|5.||Vitamin A (Retinol)
|8.||Reactive Oxygen Species (Oxygen Radicals)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|5.||Prostatectomy (Retropubic Prostatectomy)